You should also discuss if you have medical conditions including: have severe problems with your stomach, such as slowed emptying of your stomach (gastroparesis) or problems with digesting food have or have had problems with your pancreas, kidneys or liver have or have had depression or suicidal thoughts, or mental health issues are breastfeeding or plan to breastfeed
Central insulin-like growth factor-1 (IGF-1) restores whole-body insulin action in a model of age-related insulin resistance and IGF-1 decline
Damaged mitochondria leak excess electrons, causing an explosion of ROS that completely overwhelms the cell's antioxidant capacity
Wegovy (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist that was first approved in June 2021 to reduce excess body weight in adults with obesity or in overweight adults who have at least one weight-related comorbid condition
Furthermore, the efficacy of liraglutide is not altered by area postrema (AP) or PVH ablation or by vagal lesions (8, 20)
The duty to warn in pharmaceutical law runs primarily from the manufacturer to the prescribing physician, a doctrine called the "learned intermediary rule." However, when manufacturers allegedly fail to provide adequate safety information to physicians, that failure can be the foundation of a claim, even if the prescription itself was legitimate